Pilot study of vascular health in survivors of osteosarcoma.

Pubmed ID: 23720361

Pubmed Central ID: PMC3968821

Journal: Pediatric blood & cancer

Publication Date: Oct. 1, 2013

MeSH Terms: Humans, Male, Adult, Female, Cohort Studies, Adolescent, Child, Atherosclerosis, Lipids, Dyslipidemias, Gene Expression Regulation, C-Reactive Protein, Pilot Projects, Survivors, Vascular Cell Adhesion Molecule-1, Antineoplastic Agents, Osteosarcoma, Vasculitis

Grants: 1K12RR023247, 5P01HL055552-13, K12 RR023247, P01 HL055552, 01DK072124-01A3, CA21765, P30 CA021765, R01 DK072124

Authors: Mulrooney DA, Ness KK, Solovey A, Hebbel RP, Neaton JD, Kelly AS, Neglia JP, Huang S, Clohisy DR

Cite As: Mulrooney DA, Ness KK, Huang S, Solovey A, Hebbel RP, Neaton JD, Clohisy DR, Kelly AS, Neglia JP. Pilot study of vascular health in survivors of osteosarcoma. Pediatr Blood Cancer 2013 Oct;60(10):1703-8. Epub 2013 May 30.

Studies:

Abstract

BACKGROUND: Cardiovascular-related toxicities have been reported among survivors of osteosarcoma. METHODS: Fasting blood samples from 24 osteosarcoma survivors were analyzed for high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein-ß, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and surface expression of vascular cell adhesion molecule-1 (VCAM-1). Values were compared to subjects in the natural history Coronary Artery Risk Development in Young Adults (CARDIA) cohort study except for CECs and VCAM-1 expression, which were compared to controls studied at the University of Minnesota Lillehei clinical trials unit. PROCEDURE: Survivors (54.2% male), median age 18 years (9-32) at diagnosis, 36.5 years (20-56) at evaluation were treated with a variety of chemotherapeutic exposures, all but one were exposed to doxorubicin (median dose 450 mg/m(2) ; range: 90-645 mg/m(2)), 14 (58.3%) received cisplatin, and 3 (12.5%) were exposed to carboplatin. Two survivors (8.3%) received radiation therapy for disease relapse. Compared to CARDIA subjects, mean hsCRP (3.0 mg/L ± 2.0 vs. 1.6 ± 2.3), triglycerides (151 mg/dl ± 81.7 vs. 95.4 ± 101.3), lipoprotein (a) (34.9 mg/dl ± 17.7 vs. 13.8 ± 22.0), and fibrinogen (315.0 mg/dl ± 49.3 vs. 252.4 ± 61.7) were significantly elevated. The number of CECs (0.47 cells/ml ± 2.5 vs. 0.92 ± 2.5) did not differ while surface expression of VCAM-1 (86.4% ± 34.0 vs. 42.1 ± 33.8) was significantly elevated compared to controls. CONCLUSIONS: Among survivors of osteosarcoma, assessed a median of 14 years from diagnosis, there is evidence of vascular inflammation, dyslipidemia, and early atherogenesis.